A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2

作     者：Zhe-Rui Zhang Ya-Nan Zhang Xiao-Dan Li Hong-Qing Zhang Shu-Qi Xiao Fei Deng Zhi-Ming Yuan Han-Qing Ye Bo Zhang Zhe-Rui Zhang;Ya-Nan Zhang;Xiao-Dan Li;Hong-Qing Zhang;Shu-Qi Xiao;Fei Deng;Zhi-Ming Yuan;Han-Qinq Ye;Bo Zhang

作者机构：Key Laboratory of Special Pathogens and BiosafetyWuhan Institute of VirologyCenter for Biosafety Mega-ScienceChinese Academy of Sciences430071 WuhanChina University of Chinese Academy of Sciences100049 BeijingChina Hunan Normal UniversitySchool of Medicine410081 ChangshaChina State Key Laboratory of Virology and National Virus Resource CenterWuhan Institute of VirologyChinese Academy of Sciences430071 WuhanHubeiChina 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2020年第5卷第1期

页      面：667-669页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 10[医学] 

基　　金：supported by the National Key Research and Development Program of China(2018YFA0507201). 

主　　题：acute respiratory compounds 

摘      要：Dear Editor,Coronavirus disease 2019(COVID-19),caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),has spread rapidly and developed into a global pandemic since its outbreak in December 2019.Currently,there is no antiviral treatment available for human use.Numerous compounds,such as remdesivir and chloroquine,have been reported to inhibit SARS-CoV-2 replication effectively in vitro,but for most of them,the in vivo efficacies against SARS-CoV-2 are still under clinical studies,and for chloroquine,a drug with prominent in vitro antiviral activity,it has been found no beneficial effect for COVID-19 patients in the recent largest study.It is thus urgent to speed up large-scale screening to discover drug candidates to treat COVID-19.